GlassScriptPhysician profile
Walter Little
NPI 1760460208
$9,246.92
in general payments reported to CMS, 2019-2025
53 companies · $996 in 2025
The $996 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $915 · 2021: $1,089 · 2022: $1,802 · 2023: $1,636 · 2024: $1,844 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,992.77 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $784.97 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $760.47 | 2019-2025 | Erleada, Akeega, Balversa |
| Dendreon Pharmaceuticals LLC | $640.21 | 2019-2025 | Provenge |
| Pfizer INC. | $602.45 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $554.43 | 2021-2025 | Prolaris |
| Merck Sharp & Dohme LLC | $300.94 | 2021-2025 | Lynparza, Keytruda, Welireg |
| Abbvie INC. | $250.75 | 2019-2025 | |
| Urovant Sciences INC | $249.63 | 2021-2022 | |
| Myovant Sciences INC. | $241.30 | 2021-2022 | |
| Tolmar, INC. | $234.60 | 2023-2025 | Eligard, Jatenzo |
| Endo Pharmaceuticals INC. | $219.90 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $199.62 | 2020-2022 | |
| Medtronic USA, INC. | $182.18 | 2020 | |
| Axonics, INC. | $168.77 | 2020-2023 | Axonics |
Show all 51 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$256,451.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.